<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35243950</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1365-2060</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>54</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of medicine</Title>
          <ISOAbbreviation>Ann Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model.</ArticleTitle>
        <Pagination>
          <StartPage>743</StartPage>
          <EndPage>753</EndPage>
          <MedlinePgn>743-753</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/07853890.2022.2045347</ELocationID>
        <Abstract>
          <AbstractText><b>Background:</b> Previous studies have proven that Purinostat Mesylate (PM) is a new HDAC inhibitor and exhibits significant antitumor efficacy. However, the clinical application of PM was greatly limited by its poor solubility in water and low bioavailability.<b>Objective:</b>To increase the solubility of PM through pharmaceutical research, and prepare it into an injection that meets the needs of intravenous use to promote its clinical application.<b>Methods</b>The prepared PM/HP-β-CD inclusion complex was studied by computer simulation, fourier transform infrared spectroscopy (FT-IR), nuclear magnetic resonance (1H-NMR spectroscopy), and scanning electron microscopy (SEM). Then, the antitumor effects of PM/HP-β-CD inclusion complex were studied by in vitro cytotoxicity assay, apoptosis assay, pharmacokinetic study and in vivo antitumor assay.<b>Results:</b>Phase Solubility Analysis revealed that PM and HP-β-CD were compatible and the solubility of PM increased almost 220 times, to 2.02 mg/mL. The interaction mechanism studies revealed that PM could be embedded into the cavity of HP-β-CD through the side of the aminobenzene ring. Cell viability and apoptosis assays showed that PM/HP-β-CD complex maintained the good anti-cancer activity of PM, and PM/HP-β-CD complex has a better anti-tumor effect and lower toxicity than LBH589 and Hyper-CVAD/RTX in vivo. All the results suggest that HP-β-CD can solve the problem of PM administration and provide a way for clinical application of PM.<b>Conclusions:</b> In this study, an injectable formulation of PM in HP-β-CD (10% w/v) was prepared to improve its water solubility. Our research provides a way for clinical administration of PM, which has been under phase I clinical trial for the treatment of relapsed or refractory B-cell-related hematologic malignancies in China and the USA.KEY MESSAGESWe developed a preparation of Purinostat Mesylate that can be administered intravenously, reducing the toxicity associated with oral administration.This preparation has an outstanding therapeutic effect on SU-DHL-6 xenograft tumour, indicating its clinical value, which has been under phase I clinical trial for the treatment of relapsed or refractory B-cell-related haematologic malignancies in China and the USA.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Zejiang</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0003-1608-8361</Identifier>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wen</LastName>
            <ForeName>Jiaolin</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-5368-5942</Identifier>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>West China-California Research Center for Predictive Intervention Medicine, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Yaohui</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pei</LastName>
            <ForeName>Heying</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Minghai</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bai</LastName>
            <ForeName>Peng</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Zhuang</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Lijuan</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-8076-163X</Identifier>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Chengdu Zenitar Biomedical Technology Co., Ltd, Biomedical innovation Incubation Park, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ann Med</MedlineTA>
        <NlmUniqueID>8906388</NlmUniqueID>
        <ISSNLinking>0785-3890</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008698">Mesylates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1I96OHX6EK</RegistryNumber>
          <NameOfSubstance UI="D000073738">2-Hydroxypropyl-beta-cyclodextrin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000073738" MajorTopicYN="N">2-Hydroxypropyl-beta-cyclodextrin</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002152" MajorTopicYN="N">Calorimetry, Differential Scanning</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008698" MajorTopicYN="Y">Mesylates</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017550" MajorTopicYN="N">Spectroscopy, Fourier Transform Infrared</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Purinostat mesylate</Keyword>
        <Keyword MajorTopicYN="Y">SU-DHL-6 cell line</Keyword>
        <Keyword MajorTopicYN="Y">anti-tumour</Keyword>
        <Keyword MajorTopicYN="Y">injectable formulation</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>8</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35243950</ArticleId>
        <ArticleId IdType="pmc">PMC8903780</ArticleId>
        <ArticleId IdType="doi">10.1080/07853890.2022.2045347</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Furutani E, Shimamura A.. 
Germline genetic predisposition to hematologic malignancy. J Clin Oncol. 2017;35(9):1018–1028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5559882</ArticleId>
            <ArticleId IdType="pubmed">28297620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torre LA, Bray F, Siegel RL, et al. . 
Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25651787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferlay J, Soerjomataram I, Dikshit R, et al. . 
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25220842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fitzmaurice C, Allen C, Barber RM, et al. . 
Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6103527</ArticleId>
            <ArticleId IdType="pubmed">27918777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parkin DM, Bray F, Ferlay J, et al. . 
Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15761078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferlay J, Colombet M, Soerjomataram I, et al. . 
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30350310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel RL, Miller KD, Jemal A.. 
Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29313949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esteve-Arenys A, Valero JG, Chamorro-Jorganes A, et al. . 
The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. Oncogene. 2018;37(14):1830–1844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29353886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aukema SM, Siebert R, Schuuring E, et al. . 
Double-hit B-cell lymphomas. Blood. 2011;117(8):2319–2331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21119107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narita T, Weinert BT, Choudhary C.. 
Functions and mechanisms of non-histone protein acetylation. Nat Rev Mol Cell Biol. 2019;20(3):156–174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30467427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buuh ZY, Lyu Z, Wang RE.. 
Interrogating the roles of post-translational modifications of non-histone proteins. J Med Chem. 2018;61(8):3239–3252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28505447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Wang X, Xiang W, et al. . 
Development of purine-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities. J Med Chem. 2016;59(11):5488–5504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27186676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, Qiu Q, Tang M, et al. . 
Purinostat mesylate is a uniquely potent and selective inhibitor of HDACs for the treatment of BCR-ABL-induced B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2019;25(24):7527–7539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31439580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brewster ME, Loftsson T.. 
Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev. 2007;59(7):645–666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17601630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldsmith SD, McDowell A.. 
Designing a formulation of the nootropic drug aniracetam using 2-hydroxypropyl-beta-cyclodextrin suitable for parenteral administration. Pharmaceutics. 2018;10(4):240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6320825</ArticleId>
            <ArticleId IdType="pubmed">30453664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiu N, Cheng X, Wang G, et al. . 
Inclusion complex of barbigerone with hydroxypropyl-β-cyclodextrin: preparation and in vitro evaluation. Carbohydr Polym. 2014;101:623–630.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24299819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang PH, Hu SCS, Yen FL, et al. . 
Improvement of skin penetration, antipollutant activity and skin hydration of 7,3',4'-trihydroxyisoflavone cyclodextrin inclusion complex. Pharmaceutics. 2019;11(8):399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6723501</ArticleId>
            <ArticleId IdType="pubmed">31398912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gould S, Scott RC.. 
2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol. 2005;43(10):1451–1459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16018907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higuchi TA, Connors KA.. 
Phase-solubility techniques. New York (NJ): Wiley-Interscience; 1965. p. 117–212.</Citation>
        </Reference>
        <Reference>
          <Citation>Li YF, Jin J, Guo Q, et al. . 
Complexation of synthetic CDM-AM copolymer with natamycin and carbendazim to improve solubility and fungicidal activity. Carbohydr Polym. 2015;125:288–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25857986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge X, Huang Z, Tian S, et al. . 
Complexation of carbendazim with hydroxypropyl-beta-cyclodextrin to improve solubility and fungicidal activity. Carbohydr Polym. 2012;89(1):208–212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24750625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohammad RM, Al-Katib A, Aboukameel A, et al. . 
Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol Cancer Ther. 2003;2(12):1361–1368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14707277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toner LE, Vrhovac R, Smith EA, et al. . 
The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res. 2006;12(3 Pt 1):924–932.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16467107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma SX, Chen W, Yang XD, et al. . 
Alpinetin/hydroxypropyl-beta-cyclodextrin host-guest system: preparation, characterization, inclusion mode, solubilization and stability. J Pharm Biomed Anal. 2012;67–68:193–200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22633603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J, Xie C, Edwards H, et al. . 
Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells. Oncotarget. 2017;8(4):6319–6329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5351634</ArticleId>
            <ArticleId IdType="pubmed">28030834</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
